About this visual
A single visual bringing together five retatrutide trial readouts.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Originally posted Jul 2026 · By Joe Zucchi, PA-C, MPAS
1024 × 1536 px · PDF includes the original image and a link to this page.
A single visual bringing together five retatrutide trial readouts.
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.

A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.

A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
🚨 We now have results from five positive Phase 3 trials of retatrutide!
Retatrutide is Eli Lilly and Company’s investigational once-weekly GIP, GLP-1 and glucagon triple agonist.
I created an infographic to bring the major findings together in one easy-to-scan summary.
🔹 TRIUMPH-1 | Obesity or overweight without diabetes
At 80 weeks, the 12 mg dose produced:
• 28.3% average weight loss
• 70.3 lb average weight loss
• 45.3% lost at least 30% of body weight
• 65.3% reached a BMI below 30
• 33.3% reached a BMI below 25
In the extension group with baseline BMI ≥35, average weight loss reached 30.3% at 104 weeks. Sleep apnea severity decreased by up to 60.6%, and knee osteoarthritis pain decreased by up to 73.1%.
🔹 TRIUMPH-2 | Obesity or overweight with type 2 diabetes
At 80 weeks, the 12 mg dose produced:
• 20.8% average weight loss
• 49.6 lb average weight loss
• 1.5 percentage-point A1C reduction
The greatest A1C reduction was 1.6 points with 9 mg.
🔹 TRIUMPH-3 | Severe obesity with established cardiovascular disease
At 80 weeks, the 12 mg dose produced:
• 22.6% average weight loss
• 55.8 lb average weight loss
• 37.0% reduction in triglycerides
• 9.3 mmHg reduction in systolic blood pressure
• 19 cm reduction in waist circumference
• 51.2% reduction in hs-CRP
🔹 TRIUMPH-4 | Obesity or overweight with knee osteoarthritis
At 68 weeks, the 12 mg dose produced:
• 28.7% average weight loss
• 71.2 lb average weight loss
• 39.4% lost at least 30% of body weight
• 23.7% lost at least 35%
Knee-pain scores improved by 74.3%, physical-function scores improved by 73.7%, and about 12% of participants were completely free from knee pain at the end of the trial.
🔹 TRANSCEND-T2D-1 | Early type 2 diabetes
At 40 weeks, the 12 mg dose produced:
• 16.8% average weight loss
• 36.6 lb average weight loss
• 1.9 percentage-point A1C reduction
The greatest A1C reduction was 2.0 points with 9 mg. Across retatrutide groups, up to 90% achieved A1C <7%, 85% achieved A1C ≤6.5%, and 46% achieved A1C <5.7%.
Across these five trials, retatrutide has shown substantial effects on weight, glycemic control, osteoarthritis symptoms, sleep apnea severity and multiple cardiometabolic risk factors.
#Retatrutide #ObesityMedicine #GLP1 #Type2Diabetes #ClinicalTrials #CardiometabolicHealth #EvidenceBasedMedicine